Specificity and Diversity of Antibodies to *Mycobacterium tuberculosis* Arabinomannan

Josephine Anne D. Navoa,¹ Suman Lal,² Liise-Anne Pirofski,³,⁴ Gary R. McLean,⁴† Zhongdong Dai,⁵ John B. Robbins,⁵ Rachel Schneerson,⁵ Arturo Casadevall,³,⁴ and Aharon Glatman-Freedman¹*

Departments of Pediatrics,¹ Medicine,³ and Microbiology and Immunology,⁴ and Albert Einstein College of Medicine, Bronx, and Department of Pathology, New York University School of Medicine, New York,² New York, and National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland²

Received 27 June 2002/Returned for modification 6 September 2002/Accepted 14 October 2002

Arabinomannan (AM) is a polysaccharide antigen of the mycobacterial capsule. However, it is uncertain whether AM constitutes an immunologically distinct fraction of *Mycobacterium tuberculosis*. In this study, we analyzed the repertoire and specificity of antibodies to AM by using AM-binding murine monoclonal antibodies (MAbs) and human serum samples. Murine MAbs were found to be diverse in their specificity to AM and cross-reactivity with other arabinose-containing mycobacterial polysaccharides, with MAb 9d8 binding exclusively to AM. Human antibodies to AM were detected in serum samples from patients with pulmonary tuberculosis (TB), as well as in those from healthy, purified protein derivative-negative controls, with significantly higher titers among patients. The binding of human antibodies to AM was inhibited by MAb 9d8 in three patients with TB but not in controls. MAb 5c11, which recognizes other mycobacterial arabinose-containing carbohydrates in addition to AM, inhibited the binding of serum samples from 75% of patients and 76% of controls. Analysis of human antibodies with murine MAbs to human V₃₅ determinants demonstrated diversity among antibodies to AM with qualitative and quantitative differences compared with antibodies to lipoarabinomannan. In summary, our study suggests that antibodies to AM are diverse and heterogeneous with respect to antigen recognition and V₃₅ determinant expression, with human serum samples containing different subsets of antibodies to AM with the specificities of AM-binding murine MAbs. One MAb and a subset of human antibodies bind AM specifically, suggesting that this polysaccharide is antigenically distinct and is expressed in human infection.

Tuberculosis (TB) is a leading cause of mortality worldwide, and it is estimated that 1.86 billion people are infected with *Mycobacterium tuberculosis* (13). Contributing factors to this severe health problem are the human immunodeficiency virus epidemic, the long and complicated course of treatment, drug resistance, and a lack of efficient diagnostic and preventive modalities. In addition, we lack a full understanding of the immunopathogenesis of TB. Our group is interested in the immunopathogenesis of TB. We analyzed the repertoire and specificity of antibodies to AM by using AM-binding murine monoclonal antibodies (MAbs) and human serum samples. Murine MAbs were found to be diverse in their specificity to AM and cross-reactivity with other arabinose-containing mycobacterial polysaccharides, with MAAb 9d8 binding exclusively to AM. Human antibodies to AM were detected in serum samples from patients with pulmonary tuberculosis (TB), as well as in those from healthy, purified protein derivative-negative controls, with significantly higher titers among patients. The binding of human antibodies to AM was inhibited by MAAb 9d8 in three patients with TB but not in controls. MAAb 5c11, which recognizes other mycobacterial arabinose-containing carbohydrates in addition to AM, inhibited the binding of serum samples from 75% of patients and 76% of controls. Analysis of human antibodies with murine MAbs to human V₃₅ determinants demonstrated diversity among antibodies to AM with qualitative and quantitative differences compared with antibodies to lipoarabinomannan. In summary, our study suggests that antibodies to AM are diverse and heterogeneous with respect to antigen recognition and V₃₅ determinant expression, with human serum samples containing different subsets of antibodies to AM with the specificities of AM-binding murine MAbs. One MAb and a subset of human antibodies bind AM specifically, suggesting that this polysaccharide is antigenically distinct and is expressed in human infection.

Arabinomannan (AM) is a polysaccharide antigen of the mycobacterial capsule. However, it is uncertain whether AM constitutes an immunologically distinct fraction of *Mycobacterium tuberculosis*. In this study, we analyzed the repertoire and specificity of antibodies to AM by using AM-binding murine monoclonal antibodies (MAbs) and human serum samples. Murine MAbs were found to be diverse in their specificity to AM and cross-reactivity with other arabinose-containing mycobacterial polysaccharides, with MAAb 9d8 binding exclusively to AM. Human antibodies to AM were detected in serum samples from patients with pulmonary tuberculosis (TB), as well as in those from healthy, purified protein derivative-negative controls, with significantly higher titers among patients. The binding of human antibodies to AM was inhibited by MAAb 9d8 in three patients with TB but not in controls. MAAb 5c11, which recognizes other mycobacterial arabinose-containing carbohydrates in addition to AM, inhibited the binding of serum samples from 75% of patients and 76% of controls. Analysis of human antibodies with murine MAbs to human V₃₅ determinants demonstrated diversity among antibodies to AM with qualitative and quantitative differences compared with antibodies to lipoarabinomannan. In summary, our study suggests that antibodies to AM are diverse and heterogeneous with respect to antigen recognition and V₃₅ determinant expression, with human serum samples containing different subsets of antibodies to AM with the specificities of AM-binding murine MAbs. One MAb and a subset of human antibodies bind AM specifically, suggesting that this polysaccharide is antigenically distinct and is expressed in human infection.

Arabinomannan (AM) is a polysaccharide antigen of the mycobacterial capsule. However, it is uncertain whether AM constitutes an immunologically distinct fraction of *Mycobacterium tuberculosis*. In this study, we analyzed the repertoire and specificity of antibodies to AM by using AM-binding murine monoclonal antibodies (MAbs) and human serum samples. Murine MAbs were found to be diverse in their specificity to AM and cross-reactivity with other arabinose-containing mycobacterial polysaccharides, with MAAb 9d8 binding exclusively to AM. Human antibodies to AM were detected in serum samples from patients with pulmonary tuberculosis (TB), as well as in those from healthy, purified protein derivative-negative controls, with significantly higher titers among patients. The binding of human antibodies to AM was inhibited by MAAb 9d8 in three patients with TB but not in controls. MAAb 5c11, which recognizes other mycobacterial arabinose-containing carbohydrates in addition to AM, inhibited the binding of serum samples from 75% of patients and 76% of controls. Analysis of human antibodies with murine MAbs to human V₃₅ determinants demonstrated diversity among antibodies to AM with qualitative and quantitative differences compared with antibodies to lipoarabinomannan. In summary, our study suggests that antibodies to AM are diverse and heterogeneous with respect to antigen recognition and V₃₅ determinant expression, with human serum samples containing different subsets of antibodies to AM with the specificities of AM-binding murine MAbs. One MAb and a subset of human antibodies bind AM specifically, suggesting that this polysaccharide is antigenically distinct and is expressed in human infection.

Tuberculosis (TB) is a leading cause of mortality worldwide, and it is estimated that 1.86 billion people are infected with *Mycobacterium tuberculosis* (13). Contributing factors to this severe health problem are the human immunodeficiency virus epidemic, the long and complicated course of treatment, drug resistance, and a lack of efficient diagnostic and preventive modalities. In addition, we lack a full understanding of the immunopathogenesis of TB. Our group is interested in the immunopathogenesis of TB. We analyzed the repertoire and specificity of antibodies to AM by using AM-binding murine monoclonal antibodies (MAbs) and human serum samples. Murine MAbs were found to be diverse in their specificity to AM and cross-reactivity with other arabinose-containing mycobacterial polysaccharides, with MAAb 9d8 binding exclusively to AM. Human antibodies to AM were detected in serum samples from patients with pulmonary tuberculosis (TB), as well as in those from healthy, purified protein derivative-negative controls, with significantly higher titers among patients. The binding of human antibodies to AM was inhibited by MAAb 9d8 in three patients with TB but not in controls. MAAb 5c11, which recognizes other mycobacterial arabinose-containing carbohydrates in addition to AM, inhibited the binding of serum samples from 75% of patients and 76% of controls. Analysis of human antibodies with murine MAbs to human V₃₅ determinants demonstrated diversity among antibodies to AM with qualitative and quantitative differences compared with antibodies to lipoarabinomannan. In summary, our study suggests that antibodies to AM are diverse and heterogeneous with respect to antigen recognition and V₃₅ determinant expression, with human serum samples containing different subsets of antibodies to AM with the specificities of AM-binding murine MAbs. One MAb and a subset of human antibodies bind AM specifically, suggesting that this polysaccharide is antigenically distinct and is expressed in human infection.

Arabinomannan (AM) is a polysaccharide antigen of the mycobacterial capsule. However, it is uncertain whether AM constitutes an immunologically distinct fraction of *Mycobacterium tuberculosis*. In this study, we analyzed the repertoire and specificity of antibodies to AM by using AM-binding murine monoclonal antibodies (MAbs) and human serum samples. Murine MAbs were found to be diverse in their specificity to AM and cross-reactivity with other arabinose-containing mycobacterial polysaccharides, with MAAb 9d8 binding exclusively to AM. Human antibodies to AM were detected in serum samples from patients with pulmonary tuberculosis (TB), as well as in those from healthy, purified protein derivative-negative controls, with significantly higher titers among patients. The binding of human antibodies to AM was inhibited by MAAb 9d8 in three patients with TB but not in controls. MAAb 5c11, which recognizes other mycobacterial arabinose-containing carbohydrates in addition to AM, inhibited the binding of serum samples from 75% of patients and 76% of controls. Analysis of human antibodies with murine MAbs to human V₃₅ determinants demonstrated diversity among antibodies to AM with qualitative and quantitative differences compared with antibodies to lipoarabinomannan. In summary, our study suggests that antibodies to AM are diverse and heterogeneous with respect to antigen recognition and V₃₅ determinant expression, with human serum samples containing different subsets of antibodies to AM with the specificities of AM-binding murine MAbs. One MAb and a subset of human antibodies bind AM specifically, suggesting that this polysaccharide is antigenically distinct and is expressed in human infection.

Arabinomannan (AM) is a polysaccharide antigen of the mycobacterial capsule. However, it is uncertain whether AM constitutes an immunologically distinct fraction of *Mycobacterium tuberculosis*. In this study, we analyzed the repertoire and specificity of antibodies to AM by using AM-binding murine monoclonal antibodies (MAbs) and human serum samples. Murine MAbs were found to be diverse in their specificity to AM and cross-reactivity with other arabinose-containing mycobacterial polysaccharides, with MAAb 9d8 binding exclusively to AM. Human antibodies to AM were detected in serum samples from patients with pulmonary tuberculosis (TB), as well as in those from healthy, purified protein derivative-negative controls, with significantly higher titers among patients. The binding of human antibodies to AM was inhibited by MAAb 9d8 in three patients with TB but not in controls. MAAb 5c11, which recognizes other mycobacterial arabinose-containing carbohydrates in addition to AM, inhibited the binding of serum samples from 75% of patients and 76% of controls. Analysis of human antibodies with murine MAbs to human V₃₅ determinants demonstrated diversity among antibodies to AM with qualitative and quantitative differences compared with antibodies to lipoarabinomannan. In summary, our study suggests that antibodies to AM are diverse and heterogeneous with respect to antigen recognition and V₃₅ determinant expression, with human serum samples containing different subsets of antibodies to AM with the specificities of AM-binding murine MAbs. One MAb and a subset of human antibodies bind AM specifically, suggesting that this polysaccharide is antigenically distinct and is expressed in human infection.
forigraphy as previously described (33). AM purity was confirmed by gas-liquid chromatography and 1°C nuclear magnetic resonance spectroscopy (33). LAM and arabinogalactan (AG) were kindly provided by J. T. Belisle (Department of Microbiology, Colorado State University, Fort Collins).

MAbs D12 (IgG1), B6 (IgG2a), and 16/84 (IgG1) have been described previously (20). MAbs CS-40 (IgG1) and CS-35 (IgG3) were kindly provided by J. T. Belisle. Marine MAbs that react with human V31 determinants (kindly provided by R. Mageed, Kennedy Institute of Rheumatology, London, United Kingdom) were as follows: MAbs G6 (IgG2a) and G8 (IgG1) recognize determinants encoded by Vv31 gene family elements, and MAbs 5c11 (IgG2a), B6 (IgG1), and 16/84 (IgG1) recognize determinants encoded by Vv31 gene family elements.

Preparation of RNA and reverse transcription-PCR for murine MAbs sequencing. For RNA preparation, hybridoma cells producing MAbs 9d8 and 5c11 were grown in Dulbecco's modified Eagle's medium with fetal calf serum, NCTC 109, and nonessential amino acids. RNA was prepared with Trizol reagent (GIBCO, Grand Island, N.Y.) in accordance with the manufacturer's instructions. Briefly, 1 ml of Trizol reagent was used per 10⁶ log-phase cells and 10 ml of RNA was used immediately following preparation for cDNA synthesis from mRNA, with oligo(dT) primer and superscript II reverse transcriptase (GIBCO). The cDNA encoding the variable domains of 9d8 and 5c11 hybridoma immunoglobulin was then generated by PCR with universal 5′ (sense) variable-region and specific 3′ (antisense) constant-region primers (9) as follows: 5′ VH Uni, TGGAGTGGCG; 3′ VH Uni, CTGGAGGAGTGC; 5′ Va Uni, GACATCTGAACTGACCT; 3′ Va Uni, 3′ mcSp, AGACAGATGGGCTGTTTGGG; 3′ mcSp, AGACATTTGAGGACTGACT; 3′ mcSp, TGGATACTGGTTGAGCAGTACG. A sample of 10 μg of template was used in the PCR with 2.5 mM each deoxynucleoside triphosphate and 125 mM each primer under the following conditions with Taq polymerase (Roche, Mannheim, Germany): 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min 30 s for 40 cycles, followed by a final 10-min extension at 72°C. Purified PCR products (QIAGEN) were then ligated into pCR2.1 (Invitrogen, Carlsbad, Calif.) in accordance with the manufacturer's instructions. Constructs containing inserts were detected by restriction digestion with EcoRI (Roche) and visualized by 2% agarose gel electrophoresis. The amplified variable-domain cDNAs of several selected clones were sequenced bidirectionally by automated gel sequencing (AECOM Cancer Center Sequencing Facility) with primers M13R and M13F.

Human serum samples. Serum samples were collected from 20 patients with pulmonary TB (patients) prior to treatment and 17 purified protein derivative-negative adults (controls). Written informed consent was obtained from all subjects, the experimental protocol was approved by the institutional ethical review board of the Albert Einstein College of Medicine and the New York University Medical School, and the guidelines for human experimentation were followed. Patients ranged in age from 16 to 65 years, with a mean of 32 years (17 males, two females, and one person of unknown gender). Controls ranged in age from 21 to 41 years, with a mean age of 30 years (nine males and eight females). For antibody measurement, serum samples were obtained from another cohort of 11 males, two females, and one person of unknown gender). Controls ranged in age from 21 to 56 years and an average age of 35 years.

For antigen detection, serum samples were obtained from another cohort of 11 males, two females, and one person of unknown gender). Controls ranged in age from 21 to 56 years and an average age of 35 years. Serum samples used for antibody measurements were heated to 56°C for 1 min 30 s for 40 cycles, followed by a final 10-min extension at 72°C. Carbonate buffer alone was added to undiluted serum samples to a 10 μg/ml concentration of 10 μg/ml was added. Plates were incubated at 37°C for 1 h. GAM-AP IgM at 1 μg/ml was added prior to the addition of PNP. A solution of 1% BSA was added to control wells. After incubation at 37°C for 1 h, GAM-AP IgM at 1 μg/ml was added prior to the addition of PNP. For a competition ELISA with 5c11 and CS35 was done by coating microtiter plates with 3 μg of AM per ml and blocking with 3% BSA as described above. MAB 5c11 was added at a starting concentration of 25 μg/ml and serially diluted. Immediately, MAB CS35 or 3E5 (an irrelevant control), at a concentration of 5 μg/ml in 1% BSA in TBS, was added to designated wells. A solution of 1% BSA was added to control wells. After incubation at 37°C for 1 h, GAM-AP IgM at 1 μg/ml was added prior to the addition of PNP. For a competition ELISA with human serum samples and AM-binding murine MAbs, microtiter plates were coated with AM at a concentration of 3 μg/ml and blocked as described above. Serum samples were added at a starting dilution of 1:100 in 1% BSA and serially diluted. Immediately, MAB 9d8 or 5c11, at a concentration of 25 μg/ml, was added and the plates were incubated at 37°C for 1 h. GAH-AP IgG, at a concentration of 1 μg/ml, was added prior to the addition of PNP. MABs 3E5 (IgG3) and 2D10 (IgM) to Cryptococcus neoformans glucuronoxymannan (25) were used as negative controls.

Results were read, and the presence or absence of inhibition was determined. In those assays demonstrating inhibition, the percentage of maximal inhibition was determined by identifying the point of maximal inhibition on the graph (see Fig. 1) and calculating the percent reduction of A405 in the presence of MAB for that point. V31 determinant expression by antibodies to AM and LAM. The ELISA used was adapted from an assay previously described (1, 17, 18). Briefly, microtiter plates were coated with 3 μg of AM or LAM per ml in carbonate buffer. Plates were incubated at 37°C for 1 h and blocked with 200 μl of 5% BSA in TBS. Serum samples were added at a starting dilution of 1:50, serially diluted, and incubated for 1.5 h. MAB directed to human V31 determinants at a concentration of 5 μg/ml in 1% BSA in TBS was then added to designated wells. After incubation and washing, 50 μl of GAM-AP IgG1 or IgG2a at a concentration of 1 μg/ml was added. Plates were developed as described above. Absorbance of 1.5 times the background absorbance was considered positive.

AM detection in serum. Detection of AM in serum was done with a capture ELISA similar to that which was previously described (33). Briefly, microtiter plate wells were coated with 50 μl of unlabeled goat anti-mouse IgG3 per ml in TBS; this was followed by blocking with 200 μl of 1% BSA in TBS. MAB 9d8, at a concentration of 1 μg/ml, was added to each well, and the plates were incubated for 1 h at 37°C. Undiluted serum samples (predigested with proteinase K as described below) were then added and serially diluted, and the plates were incubated for 1 h at 37°C. The plates were then incubated with MAB 5c11 at a concentration of 10 μg/ml and after further washing, 1 μg of GAM-AP IgM per ml was added to all of the wells. Washes between the various steps and development of plates were done as described above. Purified AM was used as a positive control.

Preparation of samples for capture ELISA. The serum samples used for detection of AM were digested with protease K (Boehringer Mannheim, Indianapolis, Ind.) to eliminate antigen-antibody complexes and other interfering proteins prior to testing by capture ELISA. Proteinase K digested in PBS was added to undiluted serum samples to a final concentration of 0.1 μg/ml. After overnight incubation at 37°C, samples were boiled for 15 min to inactivate proteinase K and centrifuged; the supernatant solution was diluted in 1% BSA and assayed by capture ELISA.

Analysis of data. Geometric mean titers of IgG and IgM of human antibodies to AM were calculated, and differences between patients and controls were analyzed by the Kruskal-Wallis test. The results of the competition ELISA were analyzed by the chi square test. Statistical significance was defined as P < 0.05.

Nucleotide sequence accession numbers. The consensus sequences obtained in this study were deposited in the GenBank database under the following accession numbers: 9d8 Vh, AJ146143; 9d8 Vc, AJ146142; 5c11 Vh, AJ146145; 5c11 Vc, AJ146144.
RESULTS

Binding of murine MAbs to AM, LAM, and AG. The binding of murine MAbs 5c11, 9d8, CS-40, and CS-35 to the mycobacterial fractions AM, LAM, and AG was assessed, and the results are shown in Table 1. All of the MAbs recognized AM. However, while MAb 9d8 recognized AM exclusively, the other three MAbs recognized other surface polysaccharides as well. MAbs 5c11 and CS-35 recognized LAM and AG in addition to AM, and MAb CS-40 recognized LAM but not AG.

Sequencing of MAb variable domains. To learn more about the differences of antibodies to AM, the VH and VK domains of murine MAbs 5c11 and 9d8 were sequenced and the sequences were deposited in the GenBank database under the accession numbers listed in Materials and Methods. Analysis of the sequences revealed that the MAbs used different germ line family sequences for VH, VK, and Jx but the same germ line family for Jx (Table 1). Comparison of these heavy- and light-chain rearranged V region sequences to similar sequences found in the GenBank database has shown that the V region rearrangement events encode various immunoglobulin binding specificities ranging from double-stranded DNA to protein epitopes (3, 4, 22, 26, 30). Measurement of IgG and IgM to AM in serum samples. IgG and IgM to AM were detected in serum samples of patients and controls (Tables 2 and 3). The geometric mean titer showed a 10-fold higher level of IgG (16,858 versus 1,579) and a 4-fold higher level of IgM (171 versus 38) in serum samples from patients compared to those from controls (Table 2). The differences were statistically significant by the Kruskal-Wallis test at $P < 0.01$ and $P < 0.05$, respectively. The predominant IgG isotype among antibodies to AM was IgG2 (Table 2), which was detected in 16 (80%) of 20 patients and 11 (65%) of 17 controls, with mean absorbances of 1.15 ± 1 and 0.29 ± 0.28, respectively. IgG1 was detected in the serum samples of seven (35%) patients, with absorbance values significantly lower than those measured for IgG2 (absorbance data not shown).

Competition ELISA. A competition ELISA was performed to determine whether IgG to AM included a subset of antibodies with MAb 9d8 specificity. Among the patients, inhibition of binding by MAb 9d8 was observed in three serum samples (those of patients B, C, and E; Table 3), representing 15% of the patient population tested. Inhibition by MAb 9d8 was not found in control serum samples. The differences between the two groups were not statistically significant ($P = 0.234$). Inhibition by MAb 9d8 was detected in individuals with a high absorbance value detected upon measurement of total IgG to AM (data not shown), and the percent maximal inhibition ranged from 44 to 81% (Fig. 1). No inhibition was observed when MAb 3E5 was used instead of MAb 9d8. Inhibition by MAb 5c11 was found in serum samples of 15 patients and 13 controls (75 and 76%, respectively). Percent maximal inhibition by MAb 5c11 ranged from 40 to 78% among patients and from 33 to 77% among the controls who demonstrated inhibition of binding (Table 3).

A competition ELISA was also performed with MAbs 5c11 and CS-35 to determine whether these MAbs, which demonstrated binding patterns similar to those of the mycobacterial carbohydrates, recognize the same epitope on these carbohydrates. The results showed no inhibition of MAb 5c11 binding to AM by MAb CS-35, suggesting that these MAbs recognize different epitopes.

VH determinant expression. Extrapolating from the murine MAb analysis, indicating that different VH gene families could encode VH regions of antibodies to AM, we utilized VH determinant expression as a tool with which to explore the diversity of human antibodies to AM. We also used this method to detect subtle similarities and differences between antibodies to AM and LAM. Antibodies to AM in serum samples of patients expressed predominantly VH determinants recognized by MAbs 16:84, D12, B6, and G8 (Fig. 2). Antibodies to AM in serum samples of controls were recognized by MAbs 16:84, D12, and B6, but little or no reactivity with MAbs G6 and G8 was detected (Fig. 2). Diversity was observed with respect to the number and composition of the VH determinants expressed by antibodies to AM in different individuals. Our results also show different patterns of VH determinant expression by antibodies to AM and LAM among different individuals. We use the term “correspondence” to describe these findings. Correspondence is defined as the presence of antibodies to both AM and LAM that are recognized by a specific anti-idiotype MAb(s). Among the patients, 40% (patients A, D, H, K, M, O, P, and R) showed complete correspondence in anti-

### TABLE 1. Analysis of murine MAbs to AM in terms of isotype, binding patterns, and gene sequencing

| MAb  | Isotype | Antigen(s) | VH family | JH family | CDR3-H | VK family | Jk family | CDR3-L |
|------|---------|------------|-----------|-----------|--------|-----------|-----------|--------|
| 5c11 | IgM     | AM, LAM, AG| 12 (subgroup 3C) | 3 | 9 | 10 (subgroup 3) | 2 | 8 |
| 9d8  | IgG3    | AM         | 7 (subgroup 2A) | 3 | 8 | 2 (subgroup 1) | 4 | 9 |
| CS-40| IgG1    | AM, LAM    | ND         | ND        | ND     | ND        | ND        | ND     |
| CS-35| IgG3    | AM, LAM, AG| ND        | ND        | ND     | ND        | ND        | ND     |

### TABLE 2. Titer and isotype determination of human antibodies to AM

| Group (no. of persons) | GMT* | % of persons expressing antibodies of subclass: | IgM | IgG | IgG1 | IgG2 | IgG3 | IgG4 |
|------------------------|------|---------------------------------------------|-----|-----|------|------|------|------|
| Pulmonary TB patients (20) | 171b | 16,858  | 35 | 80 | 0    | 0    | 0    | 0    |
| Controls (17)          | 38   | 1,579  | 0  | 65 | 6    | 6    |      |      |

* GMT: geometric mean titer.

b $P < 0.05$.

c $P < 0.01$.
body response to AM and LAM (Fig. 2). In other words, in these individuals, the results suggest that the pattern of $V_H$ determinant expression of antibodies to AM matched that of antibodies to LAM. Partial correspondence in antibody response to AM and LAM was demonstrated in 55% of the patients (patients B, C, E, F, G, I, L, N, Q, S, and T); some of their antibodies that are recognized by certain anti-idiotypic MAbs bind to either AM or LAM but not to both. In these patients, the pattern of $V_H$ determinant expression of antibodies to AM did not have an exact match with the antibodies to LAM. One individual (5%) showed no expression of the $V_H$ determinants tested. Differences and commonalities in $V_H$ determinant expression by antibodies to AM and LAM were also found in controls. However, overall, a lesser degree of $V_H$ determinant expression was detected in this group.

**DISCUSSION**

AM is a major component of the *M. tuberculosis* capsule (8). Little is known about its exact structure or biological effects or how it differs from the AM component of LAM. Previous studies by our group demonstrated that the survival of mice infected with *M. tuberculosis* precoated with MAb 9d8, directed to AM, was enhanced (36), suggesting that AM may be an immunologically important fraction. Our earlier studies also suggested that the AM antigen has unique characteristics (33). For instance, it is highly sensitive to the effect of the detergent Tween 80, which is used to grow *M. tuberculosis* in suspension (33). In fact, MAb 9d8 was generated by immunizing mice with *M. tuberculosis* grown in the absence of the detergent Tween 80 (20). A similar Tween-associated effect was not observed with LAM. In addition, its expression during growth in vitro is

**TABLE 3. Antibody response among Individuals with Pulmonary Tb and Controls**

| Subject | Titer | Predominant IgG subclass | % of maximal inhibition by: |
|---------|-------|--------------------------|---------------------------|
|         | IgM   | IgG                      | MAb 5c11 | MAb 9d8 |
| Pulmonary TB patients |       |                          |             |         |
| A       | 1:150 | 1:109,350                | IgG2       | NI      | 79      |
| B       | 1:150 | 1:36,150                 | IgG1       | 70       | 44      |
| C       | 1:50  | 1:109,350                | IgG2       | 65       | NI      |
| D       | 1:150 | 1:36,150                 | IgG1       | 46       | 81      |
| E       | 1:450 | 1:109,350                | IgG2       | 77       | NI      |
| F       | 1:1,350 | 1:1,350               | IgG2       | 56       | NI      |
| G       | 1:450 | 1:109,350                | IgG2       | 78       | NI      |
| H       | 1:50  | 1:12,150                 | IgG2       | 56       | NI      |
| I       | 1:1,350 | 1:12,150               | NR         | 57       | NI      |
| J       | 1:50  | 1:450                    | NR         | 40       | NI      |
| K       | NR    | 1:109,350                | IgG2       | NI      | NI      |
| L       | 1:4,050 | 1:12,150              | IgG2       | 58       | NI      |
| M       | 1:150 | 1:4,050                  | IgG2       | 52       | NI      |
| N       | 1:50  | 1:450                    | NR         | 67       | NI      |
| O       | 1:150 | 1:12,150                 | IgG2       | 57       | NI      |
| P       | 1:150 | 1:36,150                 | IgG2       | 63       | NI      |
| Q       | 1:150 | 1:36,150                 | IgG2       | 76       | NI      |
| R       | 1:1,350  | 1:36,150             | IgG2       | NI      | NI      |
| S       | 1:150 | 1:12,150                 | IgG2       | NI      | NI      |
| T       | 1:150 | 1:12,150                 | IgG2       | NI      | NI      |
| Controls |       |                          |             |         |
| 1       | 1:50  | 1:1,350                  | IgG2       | 68       | NI      |
| 2       | 1:1,350 | 1:4,050               | NR         | 67       | NI      |
| 3       | NR    | 1:12,150                 | IgG2       | 33       | NI      |
| 4       | NR    | 1:12,150                 | IgG2       | 59       | NI      |
| 5       | 1:50  | 1:1,350                  | NR         | 44       | NI      |
| 6       | 1:1,350 | 1:450                   | IgG2       | 51       | NI      |
| 7       | 1:50  | 1:4,050                  | NR         | 58       | NI      |
| 8       | 1:50  | 1:1,350                  | NR         | 59       | NI      |
| 9       | 1:50  | NR                       | NR         | 67       | NI      |
| 10      | 1:50  | 1:1,350                  | IgG2       | 67       | NI      |
| 11      | 1:150 | 1:4,050                  | NR         | 44       | NI      |
| 12      | 1:450 | 1:36,150                 | IgG2       | 75       | NI      |
| 13      | NR    | 1:1,350                  | IgG2       | NI      | NI      |
| 14      | NR    | 1:450                    | IgG4       | 77       | NI      |
| 15      | 1:50  | 1:4,050                  | IgG2       | NI      | NI      |
| 16      | 1:150 | 1:450                    | IgG2       | 71       | NI      |
| 17      | 1:50  | 1:4,050                  | IgG2       | 52       | NI      |

* NI, no inhibition.

b NR, nonreactive.

The limit of detection of the assay is 0.45 μg/ml. AM was not detected in any of the serum samples tested.
different from that of LAM (33). These qualities suggest that AM may possess distinct antigenic characteristics.

To evaluate antibody binding to AM, we used several MAbs generated to mycobacterial carbohydrates and compared their binding to various mycobacterial fractions. Studying the binding of murine MAbs 9d8, 5c11, CS-40, and CS-35 (Table 1) to AM and other arabinose-containing fractions of *M. tuberculosis* revealed that all four MAbs recognized AM but each differed in its characteristics of binding to the other arabinose-containing fractions. While MAb 9d8 recognizes AM exclusively (20, 36), MAbs 5c11, CS-40, and CS-35 recognized both AM and LAM. Moreover, MAbs 5c11 and CS-35 recognized the cell wall carbohydrate AG, a part of the mycolyl-AG-peptidoglycan complex. These results suggest that AM and LAM share antigenic determinants, as both were recognized by MAbs 5c11, CS-40, and CS-35. The ability of MAbs 5c11 and CS-35 to recognize AG, in addition to AM and LAM, can be explained by the cross-reactivity between AM and AG previously described (8). The exclusive binding of MAb 9d8 to AM supports the idea that, despite some antigenic similarities, AM may be structurally different from LAM. The concept that antigenic differences between AM and LAM exist is also supported by our previous studies demonstrating that the method of tissue processing required to perform immunostaining with MAb 9d8 (33) differs from that used for immunostaining with MAb 5c11 (21). The immunostaining patterns of lung tissue from mice infected with *M. tuberculosis* in the presence of these MAbs were different as well. Furthermore, while the AM epitope recognized by MAb 9d8 is affected by the presence of Tween 80 in the *M. tuberculosis* culture medium, the epitopes recognized by MAbs CS-40 and 5c11 remain unaffected (33). These findings emphasize the uniqueness of AM and certain antibodies that are directed to it.

DNA sequencing of MAbs 5c11 and 9d8 demonstrated the usage of different VH and VK region genes by these antibodies (Table 1). The heavy- and light-chain V regions, and especially the CDR3 region, are important for antigen recognition. The differences in antigen specificity among the AM-binding MAbs are echoed by differences in variable-gene usage. The finding that MAbs that bind AM are heterogeneous in V region usage suggests that antibodies to AM are structurally diverse.

Analysis of the human antibody response to AM demonstrated that IgG and IgM to AM were detected in the serum samples of both patients and controls, with antibody titers being significantly higher in serum samples from patients. The presence of higher titers of antibodies to AM among the patients is probably due to active replication of bacilli during the disease process.
disease. In this regard, we have previously demonstrated that the titers of IgG and IgM to AM in mice infected with *M. tuberculosis* increased in direct proportion to the CFU count (33). The presence of antibodies to AM among the controls may be explained by exposure to environmental mycobacteria. Various mycobacteria can be isolated from the environment (12, 16, 23), and structural similarities between AMs of different mycobacterial species were previously described (13, 24). AM-binding MAb 9d8, for example, was previously found to recognize three mycobacterial species other than *M. tuberculosis* (*M. kansasii*, *M. gordoni*, and *M. gaseri*) (20). Several studies have provided supportive evidence for the role played by environmental exposure in eliciting immune responses (including antibodies) to mycobacterial antigens (15, 23, 29, 37).

Cross-reactivity of human antibodies induced by environmental mycobacteria could thus explain the presence of antibodies to *M. tuberculosis* AM in healthy individuals in this study. The presence of IgM to AM in controls is intriguing and may suggest recent or continuous exposure to environmental mycobacteria.

IgG2 was the predominant isotype among antibodies to AM (Tables 2 and 3). This finding is consistent with the predominance of this isotype among antibodies to other bacterial polysaccharide antigens, such as those of *Streptococcus pneumoniae*, *Haemophilius influenzae* type b (19, 32, 34), and *C. neoformans* (10), in adults. Our results are also consistent with previous studies demonstrating IgG2 predominance in the antibody response to LAM in TB and leprosy (7, 11). The stronger IgG2 response, as manifested by the higher absorbance values detected in the patients than in the controls (individual absorbance values are not shown), is most probably a reflection of the higher total IgG titers detected in the former (34). The finding of IgG1 in the serum samples of few patients is consistent with studies demonstrating that this isotype is the second most prevalent isotype elicited by bacterial polysaccharides (32, 34).

To exclude interference by AM in our assay, serum samples were tested for the presence of this antigen by capture ELISA. None of the undiluted serum samples tested demonstrated the presence of AM. The absence of AM in patients’ serum samples may be due to either small quantities of the antigen produced or rapid clearance, the latter possibly as a result of their antibody responses. Previous experiments, for instance, showed that LAM is cleared from serum within a few hours and that its clearance is enhanced by the presence of antibody (21). We hypothesize that the same effective clearance occurs with AM.

Since MAb 9d8, which binds AM exclusively, identified an immunologically important epitope of AM, we attempted to determine if antibodies with the same specificity as MAb 9d8 were present in human serum samples by using a competition ELISA. Inhibition of binding to AM by MAb 9d8 was found in three patients (Fig. 1) but not in controls. It is possible that other serum samples contained antibodies to AM with the specificity of MAb 9d8 as well; however, their titers may be below the limit of detection of our assay. Alternatively, the affinity of human antibody to AM may be stronger than that of MAb 9d8, thus preventing inhibition by the latter. Structural differences between AMs from different strains of *M. tuberculosis* may also account for the lack of inhibition in certain individuals. Inhibition of serum antibody binding by MAb 5c11 was more common than inhibition by MAb 9d8. This result is most probably due to the higher prevalence of the MAb 5c11 epitope in AM. Alternatively, MAb 5c11 may bind more strongly to AM than does MAb 9d8, thus preventing easy displacement by human antibodies to AM.

The analysis of murine MAbs (Table 1) and the competition ELISA suggest that antibodies to AM may vary in specificity and cross-reactivity. To further explore the diversity among human antibodies to AM, we used murine MAbs to human Vi4 determinants to test our samples (Fig. 2). Vi4 determinants are specific areas in the variable regions of antibodies that are coded for by specific gene families. Our results demonstrated that antibodies to AM in patients’ serum samples expressed mostly Vi4 determinants that are recognized by MAbs 16:84, D12, B6, and G8. The control antibodies expressed Vi4 determinants recognized by MAbs 16:84, D12, and B6 but little or none recognized by MAb G6 or G8. The expression of Vi4 gene family determinants (recognized by MAbs 16:84, D12, and B6) by antibodies to AM is similar to that found in the antibodies to pneumococcal polysaccharide (1), *H. influenzae* (2) and *C. neoformans* glucuronoxylomannan (17, 18). However, unlike antibodies to these polysaccharides, antibodies to AM also expressed determinants encoded by the Vi4-gene family (recognized by MAbs G6 and G8). These findings suggest that the antibody response to AM is not restricted to the expression of one or few idiotypic determinants.

We also used Vi4 determinant expression to differentiate between the repertoire of antibodies generated to AM and the repertoire of antibodies generated to LAM, as both contain arabinose and mannose. Qualitative differences and commonalities in Vi4 determinant expression were found among antibodies, from different individuals, generated to the two polysaccharides (Fig. 2) in both patients and controls. The differences noted between the antibody responses to AM and LAM support the notion that these polysaccharides have antigenic differences. It also suggests that certain individuals may differ in the ability to elicit antibody responses to these antigens. The similarities in Vi4 determinant expression of antibodies to AM and LAM seen among both groups, particularly in the TB patients, may be explained by a possible cross-reactivity of antibodies to AM and LAM or by epitopes shared by both fractions. MAbs 5C11, CS40, and CS35 (Table 1), for instance, were shown to react with both AM and LAM. Some individuals in both groups appear to have antibodies to either AM or LAM which did not express most or any of the Vi4 determinants recognized by the Vi4 MAbs used in this study. These individuals may have antibodies to AM and LAM that express Vi4 determinants recognized by other MAbs not used in this study. Although there appears to be more Vi4 determinant expression among patients, this probably reflects the higher antibody titers among individuals in this group.

In summary, our results demonstrate the heterogeneity of the repertoire of antibodies to AM in terms of specificity, cross-reactivity, and Vi4 determinant expression. Our data also indicate that humans mount antibody responses to AM, particularly as a result of disease, and that antibodies with the specificity of MAb 9d8 to AM, which is protective against murine TB, can be found in human serum samples. The results also suggest that AM is antigenically different from LAM despite the fact that both contain arabinose and mannose.
other studies are required to define the presence of particular subsets of antibodies to AM in serum and correlate them with disease progression and outcome.

ACKNOWLEDGMENTS

A.G.-F was supported by National Institutes of Health (NIH) grants AI01691 and AI053192 and a grant from the Sequella Global Tuberculosis Foundation. A.C. is supported by NIH grants AI033142, AI033774, and HL059842. L.P. is supported by NIH grants AI045495, AI044374, and AI035370.

Many thanks to John T. Belisle for providing LAM and AG, as well as MAbs CS-40 and CS-35, as part of NIH contract NO1-AI-75320 (Tuberculosis Research Materials and Vaccine Testing). We also thank R. Mageed of the Kennedy Institute of Rheumatology, Chesterfield, Derbyshire, United Kingdom, for providing murine MAbs to human V 

REFERENCES

1. Abadi, J., J. L. Friedman, R. A. Mageed, R. Jeffers, M. C. Rodriguez-Barradas, and L. Pirofski. 1998. Human antibodies elicited by a pneumococcal vaccine express idiotypic determinants indicative of V 

2. Anderson, E. E., P. J. Shackelford, A. Quinn, P. M. Wilson, M. W. Cunningham, R. A. Insel, and W. L. Carroll. 1993. Restricted immunoglobulin V 

3. Bridges, A., A. Birch, G. Williams, M. Aguet, D. Schlattner, W. Huber, G. Garotta, and J. A. Robinson. 1995. Variable region cDNA sequences and characterization of murine anti-human interferon gamma receptor monocl

4. Brown, J. C., B. A. Brown II, Y. Li, and C. C. Hardin. 1998. Construction and characterization of a quadruplex DNA selective single-chain autoantibody from a viable moth-eaten mouse hydridoma with homology to telomeric DNA binding proteins. Biochemistry 37:16338–16348.

5. Chapman, G. B., J. H. Hanks, and J. H. Wallace. 1959. An electron microscope study of the disposition and fine structure of Mycobacterium leprae

6. Costello, A. M., A. Kumar, V. Naraya, M. S. Akbar, S. Ahmed, C. Abou-Zeid, G. A. Rook, J. Stanford, and C. Moreno. 1992. Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis? Trans. R. Soc. Trop. Med. Hyg. 86:686–692.

7. Da Costa, C. T., S. Khanolkar-Young, A. M. Elliott, K. M. Wasunna, and K. P. McAdam. 1993. Immunoglobulin G subclass responses to mycobacteri

8. Daffe, M., and P. Draper. 1988. The envelope layers of mycobacteria with reference to their pathogenicity. Adv. Microb. Physiol. 31:131–203.

9. Dattamajumdar, A. K., D. P. Jacobson, L. E. Hood, and G. E. Osman. 1996. Rapid cloning of any rearranged mouse immunoglobulin variable genes. Immunogenetics 43:1–151.

10. Deshaw, M., and L. A. Pirofski. 1995. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV

11. Dhandayuthapani, S., S. Izumi, D. Anandan, and V. N. Bhatia. 1992. Specificity of IgG subclass antibodies in different clinical manifestations of lep

12. du Moulin, G. C., K. D. Stotmeier, P. A. Pelleiter, A. Y. Tsang, and J. Hedy-White. 1988. Concentration of Mycobacterium avium by hospital hot water systems. JAMA 260:1599–1601.

13. Dye, C., S. Scheele, P. Dolin, V. Pathania, and M. C. Raviglione. 1999. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 282:677–686.

14. Ellner, J. J., and T. M. Daniel. 1979. Immunosuppression by mycobacterial arabinomannan. Clin. Exp. Immunol. 35:250–257.

15. Fairchok, M. P., J. H. Rouse, and S. L. Morris. 1995. Age-dependent humoral responses of children to mycobacterial antigens. Clin. Diagn. Lab. Immunol. 2:443–447.

16. Falkinham, J. O., II, B. C. Parker, and H. Graft. 1980. Epidemiology of infection by nontuberculous mycobacteria. I. Geographic distribution in the eastern United States. Am. Rev. Respir. Dis. 121:931–937.

17. Fleuridor, R., R. H. Lyles, and L. Pirofski. 1999. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J. In

18. Freijd, A., I. Hammersstrom, M. A. Persson, and C. I. Smith. 1984. Plasma anti-pneumococcal antibody activity of the IgG class and subclasses in otitis prone children. Clin. Exp. Immunol. 56:233–238.

19. Glatman-Freedman, A., J. J. Martin, P. F. Riska, B. R. Bloom, and A. Casadevall. 1996. Monoclonal antibodies to surface antigens of Mycobacte

20. Glatman-Freedman, A. J., J. A. Mednick, N. Lendvai, and A. Casadevall. 2000. Clearance and organ distribution of Mycobacterium tuberculosis lipoparabino

21. Kalinke, U., A. Oxenius, C. Lopez-Macias, R. M. Zinkernagel, and H. Hen

22. Larsson, L. O., B. E. Skoogh, M. W. Bentzon, M. Magnusson, J. Olofson, T. Taranger, and A. Lind. 1991. Sensitivity to sensitins and tuberculin in Swed

23. Lennard, N., A. Casadevall, Z. Liao, D. L. Goldman, J. Mukherjee, and L. Zuckier. 1988. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J. Infect. Dis. 177:1647–1659.

24. Onchamps, B., J. L. S. Lu, and I. Parikh. 1982. Monoclonal antibodies against estrogen receptor: interaction with different molecular forms and functions of the receptor. Biochemistry 21:6916–6921.

25. Mueller, C. M., and R. Jemmersson. 1997. Maturation of the antibody re

26. Orlandini, M., A. Santucci, A. Tramontano, P. Neri, and S. Oliviero. 1994. Cloning, characterization, and modeling of a monoclonal anti-human transfe

27. Pilkington, C., A. M. Costello, G. A. Rook, and J. L. Stanford. 1993. Developme

28. Puttermann, C., B. Deocharan, and B. Diamond. 2000. Molecular analysis of the autoantibody response in peptide-induced autoimmunity. J. Immunol.

29. Suda, E., P. J. Brennan, T. Herrera, and M. Torres. 1990. Evaluation of lipoparabinomannan for the serological diagnosis of tuberculosis. J. Clin. Microbiol. 28:2587–2590.

30. Sarvas, H., N. Rautonen, S. Sipinen, and O. Makela. 1989. IgG subclasses of nondisaggregated antibodies—effect of allotype G2m

31. Schwebach, J. R., A. Casadevall, R. Schneerson, S. A. Weitzman, and G. Schiffman. 1989. IgG subclasses of lipoparabinomannan are elevated in patients with and without Cryptococcus neoformans meningitis. J. Clin. Immunol. 9:259–267.

32. Siber, G. R., P. H. Schur, A. C. Allenberg, S. A. Weitzman, and G. Schiffman. 1980. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharides. Engl. J. Med. 303:178–182.

33. Sousa, A. O., S. Henry, F. M. Maroja, F. K. Lee, L. Brun, M. Singh, P. H. Lages, J. Monclar, and J. A. Guinovart. 1999. IgG subclass distribution of antibody responses to protein and polysaccharide mycobacterial antigens in leprosy and tuberculosis patients. Clin. Exp. Immunol. 114:48–55.

34. Teitelbaum, R., A. Glatman-Freedman, B. Chen, J. B. Robbins, E. Unanne, A. Casadevall, and B. R. Bloom. 1998. A MAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc. Natl. Acad. Sci. USA 95:15688–15693.

35. Thayer, W. R., Jr., C. M. Bozie, R. T. Camphas, and M. McNeil. 1990. Implications of antibodies to pyruvylated glucose in healthy populations for mycobacterioses and other infectious diseases. J. Clin. Microbiol. 28:714–718.